- Home
- SUPN vs MNKD Comparison
SUPN vs MNKD Comparison
Compare SUPN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- MNKD
- Stock Information
- Founded
- SUPN 2005
- MNKD 1991
- Country
- SUPN United States
- MNKD United States
- Employees
- SUPN N/A
- MNKD N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- MNKD Health Care
- Exchange
- SUPN Nasdaq
- MNKD Nasdaq
- Market Cap
- SUPN 1.7B
- MNKD 1.6B
- IPO Year
- SUPN 2012
- MNKD 2004
- Fundamental
- Price
- SUPN $30.76
- MNKD $4.54
- Analyst Decision
- SUPN Hold
- MNKD Buy
- Analyst Count
- SUPN 2
- MNKD 6
- Target Price
- SUPN $36.00
- MNKD $8.92
- AVG Volume (30 Days)
- SUPN 647.0K
- MNKD 2.2M
- Earning Date
- SUPN 05-07-2025
- MNKD 05-07-2025
- Dividend Yield
- SUPN N/A
- MNKD N/A
- EPS Growth
- SUPN 6500.00
- MNKD N/A
- EPS
- SUPN 1.32
- MNKD 0.10
- Revenue
- SUPN $661,817,000.00
- MNKD $285,504,000.00
- Revenue This Year
- SUPN N/A
- MNKD $14.23
- Revenue Next Year
- SUPN $9.32
- MNKD $14.56
- P/E Ratio
- SUPN $23.30
- MNKD $45.40
- Revenue Growth
- SUPN 8.94
- MNKD 43.50
- 52 Week Low
- SUPN $25.53
- MNKD $3.97
- 52 Week High
- SUPN $40.28
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- SUPN 40.39
- MNKD 28.12
- Support Level
- SUPN $29.77
- MNKD $4.34
- Resistance Level
- SUPN $34.26
- MNKD $4.72
- Average True Range (ATR)
- SUPN 1.51
- MNKD 0.21
- MACD
- SUPN -0.04
- MNKD -0.01
- Stochastic Oscillator
- SUPN 22.05
- MNKD 27.03
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.